Compare
Gilead Sciences vs AbbVie
MonkScore ranges and fundamentals, side by side
Key facts
Gilead Sciences and AbbVie: key facts
- In fiscal 2025, Gilead Sciences, Inc. reported revenue of $29.4B and net income of $8.5B.
- In fiscal 2025, AbbVie Inc. reported revenue of $61.2B and net income of $4.2B.
- Gilead Sciences, Inc.'s revenue grew 1.9% a year from fiscal 2021 to fiscal 2025.
- AbbVie Inc.'s revenue grew 2.1% a year from fiscal 2021 to fiscal 2025.
- Gilead Sciences, Inc.'s free cash flow was positive in 5 of the 5 fiscal years from 2021 to 2025.
- AbbVie Inc.'s free cash flow was positive in 5 of the 5 fiscal years from 2021 to 2025.
- In the twelve months to 30 September 2026, Gilead Sciences, Inc. reported revenue of $31.0B and net income of -$3.9B.
- In the twelve months to 30 June 2026, AbbVie Inc. reported revenue of $64.4B and net income of $6.3B.
Side by side
Gilead Sciences and AbbVie, side by side
Each figure is in the company's reporting currency, with its fiscal year or the date of its last report.
| Figure | Gilead Sciences, Inc.NASDAQ:GILD | AbbVie Inc.NYSE:ABBV |
|---|---|---|
| MonkScore | ||
| MonkScore range | 90–100as of October 2026 | 90–100as of October 2026 |
| Sector rank | 39 of 628 in Healthcare | 64 of 628 in Healthcare |
| How this score is madeDisclaimer | ||
| Profile | ||
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| Latest fiscal year | ||
| Revenue | $29.4BFY 2025 | $61.2BFY 2025 |
| Net income | $8.5BFY 2025 | $4.2BFY 2025 |
| Free cash flow | $9.5BFY 2025 | $17.8BFY 2025 |
| Operating cash flow | $10.0BFY 2025 | $19.0BFY 2025 |
| Total debt | $24.9BFY 2025 | $69.1BFY 2025 |
| Cash | $7.6BFY 2025 | $5.2BFY 2025 |
| Last 12 months | ||
| Revenue | $31.0Bto 30 September 2026 | $64.4Bto 30 June 2026 |
| Net income | -$3.9Bto 30 September 2026 | $6.3Bto 30 June 2026 |
| Free cash flow | $14.0Bto 30 September 2026 | $18.2Bto 30 June 2026 |
| Operating cash flow | $14.5Bto 30 September 2026 | $19.5Bto 30 June 2026 |
| Total debt | $26.2Bto 30 September 2026 | $70.8Bto 30 June 2026 |
| Cash | $6.4Bto 30 September 2026 | $6.6Bto 30 June 2026 |
Company pages
Each company on its own
MonkStreet provides research, not investment advice.